Abstract: There are provided tetravalent TGF? receptor-ectodomain based traps having a tailored isoform-specificity profile for neutralization of TGF? ligands, and methods of use thereof in the treatment of diseases and conditions associated with TGF?, particularly TGF?1 and TGF?3. In particular, there are provided TGF? binding agents designed to tailor TGF? isoform specificity, in order to maximize therapeutic efficacy in specific disease indications while minimizing adverse effects. The TGF? binding agents comprise two polypeptides assembled via a multimerization domain, each polypeptide having two TGF?II receptor (TGF?R) ligand-binding domains linked as a doublet, wherein the linkers are selected to tailor isoform specificity.

Abstract: The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

Abstract: The disclosure provides a compound of Formula (I), including deuterated derivatives, pharmaceutically acceptable salts, and solvates thereof, solid state forms of those compounds, compositions comprising those compounds and solid forms, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

Abstract: The disclosure provides compounds of Formula I, deuterated derivatives of those compounds, and pharmaceutically acceptable salts of those compounds and derivatives, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.

Abstract: The disclosure provides at least one compound, reiterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), reiterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

Abstract: The disclosure provides at least one entity chosen from compounds of Formula (I) pharmaceutically acceptable salts thereof, solvates of any of the foregoing, and deuterated derivatives of any of the foregoing, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.

Abstract: The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomeulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

Abstract: The present invention relates to a bulkhead shield particularly of a projectile with a pyrotechnic charge, situated between the pyrotechnic portion and the command and control portion. The bulkhead shield comprises at least: one wall pierced by a duct; an end-cap consisting of a support portion and a portion engaged in the duct leaving a space between itself and the wall of the duct, the two portions being connected by a mechanical weakness zone; the support portion pressing on the wall, at the front, so that the engaged portion separates from the support portion under the effect of an external pressure to come into contact with the inner wall of the duct and close the space. The invention applies in particular to shells whose detonation is programmed a given delay after impact on the target.

Abstract: Disclosed is a system for securing sub-munitions on board a carrier. The system uses straps. Each strap is fixed by one end to a container wall by a tensioning means, and its other end is engaged in a cylindrical lock element mounted on another wall. The cylindrical lock element is connected to a resistant torque generator device which is itself connected to a torque limiting device which gets triggered at a determined threshold value, so as to release the cylindrical lock element in rotation in order to release the end of the strap. In these systems, the straps are released less suddenly than in the known systems, and they are released with perfect simultaneity. A development enables the sub-munitions to be ejected with controlled angles of incidence in relation to the trajectory of the carrier.

Abstract: Disclosed is a protective casing for ejectable munitions, having means enabling it to be broken through, this being a necessary operation for the sub-munitions to be ejected, in the next stage, without any difficulty of breaking through and ejection. The fracture lines are obtained by means of screens of high temperature resistant fibers arranged in a plane perpendicular to the internal and external surfaces of the casing. This casing is a part obtained, for example, by fusion and molding. The screen is integrated so that, during the casting of the metal, this metal links up all the fibers forming the screen together. The invention can be applied to protective casings, notably for rockets and munitions carriers.

Abstract: A device for the impervious sealing of a structure, for example a munitions compartment of a rocket, is disclosed. This device comprises an elastic shaped section inside which the edge of the structure and rim of a lid are imperviously embedded. This device further has means for thrusting the lid outwards from the structure. This thrust pushes the rim and/or the edge out of the shaped section through the deformation of this elastic shaped section, and causes the total expulsion of lid. When the device is fitted into a rocket, the moving away of the rim modifies the aerodynamic drag coefficient (Cx) of the rocket. This difference in Cx causes the total expulsion of the lid and thus causes the structure to be opened.